Meeting
2022 ASCO Annual Meeting
Phase II, multicenter, open-label, non-randomized study of neoadjuvant chemotherapy NALIRINOX (5-FU/LV + oxaliplatin + nal-IRI) followed by chemoradiotherapy in patients with rectal cancer in a watch-and-wait program.
Authors
Cesar Gregorio Muñoz
HM-CIOCC, Madrid, Spain
Cesar Gregorio Muñoz , Maria Carmen Riesco Martinez , Lisardo Ugidos , Pilar Garcia-Alfonso , Rafael Álvarez , Paloma Peinado , Marcial García , Marisa Torres , Antonio Cubillo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer - Neo-Adjuvant/Adjuvant
Clinical Trial Registration Number
NCT04009876
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3612)
DOI
10.1200/JCO.2022.40.16_suppl.3612
Abstract #
3612
Poster Bd #
406
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TnT) with FOLFOX followed by short course radiation in locally advanced rectal cancer: A phase II study.
First Author: Janice Zhao
First Author: Florian Gebauer
Poster
2023 ASCO Annual Meeting
Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial.
First Author: Jesse Joshua Smith
Poster
2022 ASCO Gastrointestinal Cancers Symposium
NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).
First Author: Charles D. Lopez